Cigna Corporation
NYSE:CIMedical - Healthcare Plans
-$4.44 today
- Market cap
- $75.20B
- Beta
- 0.30
- P/E (TTM)
- 11.7
- EPS (TTM)
- $23.95
- Dividend yield
- 2.19%
Volume 2.49M
Average 1.61M
CI Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Cigna CorporationNYSE: CI
Depreciation & Amortization · Q3 FY2026 · quarter ended Sep 2026
Depreciation & amortization growth accelerates
Q3 FY2026 depreciation & amortization of $867M rose 24.4% year over year, ahead of the +7.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 32.4% from the prior quarter. Over 3 fiscal years it compounded at -1.9% a year.
Context
- Depreciation & amortization amounted to 1.0% of revenue in FY2025, down 0.1 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +24.4% holds above the trailing-twelve-month pace of +7.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 2.78B USD
- Year-over-year change
- +0.0%
- 4-year CAGR
- -1.3%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.78B | +0.0% |
| FY2024 | 2024-12-31 | 2.78B | -8.6% |
| FY2023 | 2023-12-31 | 3.04B | +3.3% |
| FY2022 | 2022-12-31 | 2.94B | +0.5% |
| FY2021 | 2021-12-31 | 2.92B | — |
Depreciation & Amortization vs competitors
How CI compares with its peers on the latest reported figures
- CI's LTM Sep 2026 depreciation & amortization of $2.89B is the 3rd largest of the 9 companies compared; the peer median is $1B.
- Its year-over-year change of +7.2% is the highest of 9, against a peer median of -2.8%.
- Depreciation & amortization amounts to 1.0% of revenue for CI, versus a peer median of 0.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $4.52B | -2.4% | +2.9% | 1.1% | |
| LTM Sep 2026 | $4.26B | -0.6% | +8.7% | 0.9% | |
| LTM Sep 2026 | $2.89B | +7.2% | -1.9% | 1.0% | |
| LTM Sep 2026 | $1.49B | -3.2% | -2.6% | 0.7% | |
| LTM Jun 2026 | $1.25B | -0.8% | -6.4% | 0.6% | |
| LTM Sep 2026 | $763M | -12.3% | -0.8% | 0.5% | |
| LTM Sep 2026 | $161M | -19.1% | +3.5% | 0.4% | |
| LTM Mar 2026 | $30.72M | +7.2% | +21.8% | 0.7% | |
| LTM Jun 2026 | $28.24M | -7.2% | +23.6% | 0.2% | |
| Peer median (excluding CI) | $1B | -2.8% | +3.2% | 0.7% | |
Competitors are the stored peer set for CI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 5.42B | 6.78B | 5.37B | 3.78B | 6.29B |
| Depreciation & Amortization | 2.92B | 2.94B | 3.04B | 2.78B | 2.78B |
| Deferred Income Tax | (216M) | (472M) | (1.66B) | (95M) | 326M |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 |
| Change in Working Capital | (879M) | 259M | 3.03B | 418M | (261M) |
| Accounts Receivables | (3.5B) | (2.24B) | (1.66B) | (7.37B) | (4.63B) |
| Inventory | (557M) | (1.06B) | (868M) | (1.03B) | (646M) |
| Accounts Payables | 2.04B | 1.73B | 3.48B | 1.14B | 2.8B |
| Other Working Capital | 1.14B | 1.82B | 2.08B | 7.68B | 2.22B |
| Other Non-Cash Items | (57M) | (850M) | 2.04B | 3.49B | 473M |
| Operating Cash Flow | 7.19B | 8.66B | 11.81B | 10.36B | 9.6B |
| Capital Expenditures | (1.15B) | (1.3B) | (1.57B) | (1.41B) | (1.21B) |
| Acquisitions (Net) | (1.89B) | 4.84B | (434M) | 390M | 2.39B |
| Purchases of Investments | (6.11B) | (4.32B) | (5.54B) | (2.7B) | (7.2B) |
| Sales of Investments | 5.59B | 4.11B | 2.64B | 2.45B | 2.65B |
| Other Investing Activities | (50M) | (233M) | (264M) | (838M) | (1.03B) |
| Investing Cash Flow | (3.61B) | 3.1B | (5.17B) | (2.1B) | (4.41B) |
| Debt Repayment | 657M | (2.56B) | (278M) | 1.06B | (666M) |
| Common Stock Issued | 326M | 389M | 187M | 305M | 203M |
| Common Stock Repurchased | (7.74B) | (7.61B) | (2.28B) | (7.03B) | (3.62B) |
| Dividends Paid | (1.34B) | (1.38B) | (1.45B) | (1.57B) | (1.61B) |
| Other Financing Activities | (112M) | (79M) | (469M) | (411M) | (726M) |
| Financing Cash Flow | (8.21B) | (11.24B) | (4.29B) | (7.65B) | (6.42B) |
| Effect of Forex Changes | (65M) | (86M) | 16M | (20M) | 1.35B |
| Net Change in Cash | (4.7B) | 428M | 2.36B | 594M | 126M |
| Free Cash Flow | 6.04B | 7.36B | 10.24B | 8.96B | 8.39B |
Cigna Corporation
NYSE:CI
Intrinsic Alpha fair value
Locked
Current Price
$285.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.